Theriva Biologics Q2 net loss narrows on lower R&D costs, expenses
TOVX•Analyst coverage
- The current average analyst rating on the shares is buy and the breakdown of recommendations is 2 strong buy or buy, no hold and no sell or strong sell.
- The average consensus recommendation for the biotechnology & medical research peer group is buy.
- Wall Street's median 12-month price target for Theriva Biologics Inc is $2.50, about 982.3% above its August 10 closing price of $0.23.
What drove the lower loss
- Lower administrative expenses — Q2 general and administrative expenses fell mainly due to the absence of a prior-year contingent consideration adjustment related to a clinical trial milestone.
- Reduced R&D costs — Q2 research and development expenses fell due to lower compensation and clinical trial costs for SYN-004 and SYN-020, partly offset by higher VCN-01 manufacturing and planning expenses.
| Metric | Actual |
|---|---|
| Q2 loss per share | $0.07 |
